Victory Capital Management Inc. Purchases 26,560 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Victory Capital Management Inc. boosted its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 88.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 56,640 shares of the company’s stock after purchasing an additional 26,560 shares during the quarter. Victory Capital Management Inc. owned approximately 0.11% of Tyra Biosciences worth $787,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Alta Partners Management Company L.P. bought a new position in Tyra Biosciences in the fourth quarter worth $56,716,000. US Bancorp DE bought a new position in Tyra Biosciences in the fourth quarter worth $50,000. Bank of New York Mellon Corp raised its holdings in Tyra Biosciences by 5.2% in the fourth quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock worth $626,000 after purchasing an additional 2,221 shares in the last quarter. Rhumbline Advisers raised its holdings in Tyra Biosciences by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock worth $364,000 after purchasing an additional 1,027 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Tyra Biosciences in the fourth quarter worth $149,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $10.94 on Friday. Tyra Biosciences, Inc. has a one year low of $9.93 and a one year high of $29.60. The stock has a market capitalization of $553.60 million, a PE ratio of -6.79 and a beta of 1.09. The business’s fifty day moving average is $13.14 and its 200 day moving average is $16.83.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the sale, the director now directly owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 21,998 shares of company stock valued at $344,818 over the last ninety days. Insiders own 15.40% of the company’s stock.

Analysts Set New Price Targets

TYRA has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Tuesday, February 18th. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $30.50.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.